Table 1: Baseline and follow-up characteristics of patients.

RA patients ()-value
BaselineFollow-up

Age (years)50 [38–63]
% Females71%
Symptoms duration (years)6 [3.5–9.5]
Rheumatoid factor (% positive)71
ACPA (% positive)53
Erosive (% y)59
Treatment with NSAIDs (% y)47
Treatment with DMARD (% y)100
DMARD duration (months)15 [3–51]
ESR (mm/h)28 [18–48]21 [13–26]0.0257
CRP (mg/dl)1.4 [0.7–2.0]0.3 [0.04–0.8]0.0018
Tender joint count9 [4–14]0 [0–2]0.0005
Swollen joint count7 [4–9]0 [0-0]0.0005
DAS28-CRP5.6 [5.2–6.3]2.9 [2.2–3.5]<0.0001
HAQ1.7 [0.8–2.0]0.1 [0.0–1.0]0.0059
TNFi duration (months)6 [6–12]

Data is represented as median [Interquartile range] unless stated otherwise; -value < 0.05 is considered significant; ACPA - anti-citrullinated protein antibodies; CRP – C-reactive protein; DAS – disease activity score; DMARDs – disease modifying antirheumatic drugs; ESR – erythrocyte sedimentation rate; HAQ - Health assessment questionnaire; NSAIDs - non-steroidal anti-inflammatory drugs; RA – rheumatoid arthritis; TNFi – tumor necrosis factor inhibitors; y – yes.